Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 14/20 | 0.70 |
| ▸ | BRD1 | O95696 | 7/20 | 0.70 |
| ▸ | BRD4 | O60885 | 4/20 | 0.70 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.69 |
| ▸ | BRPF3 | Q9ULD4 | 6/20 | 0.69 |
| ▸ | BRD9 | Q9H8M2 | 4/20 | 0.69 |
| ▸ | BRD7 | Q9NPI1 | 2/20 | 0.69 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.69 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.58 |
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14722196 | 0.83 | BRPF1 (1.00) | BRPF1BRD1BRD4HDAC8BRPF3 | |
| SCHEMBL29823517 | 0.82 | BRPF1 (1.00) | BRPF1BRD1BRD4HDAC8BRPF3 | |
| SCHEMBL17560720 | 0.82 | BRPF1 (1.00) | BRPF1BRD1BRD4HDAC8BRPF3 | |
| SCHEMBL23318384 | 0.72 | BRPF1 (0.82) | BRPF1BRD1BRD4HDAC8BRPF3 | |
| SCHEMBL17560657 | 0.71 | BRPF1 (0.73) | BRPF1BRD1BRD4HDAC8BRPF3 | |
| SCHEMBL17560647 | 0.70 | BRPF1 (1.00) | BRPF1BRD1BRD4HDAC8BRPF3 | |
| SCHEMBL17560651 | 0.69 | BRPF1 (0.63) | BRPF1BRD1BRD4HDAC8BRPF3 | |
| SCHEMBL17560663 | 0.69 | BRPF1 (1.00) | BRPF1BRD1BRD4BRPF3BRD9 | |
| SCHEMBL17560672 | 0.68 | BRPF1 (0.78) | BRPF1BRD1BRD4HDAC8BRPF3 | |
| SCHEMBL17560675 | 0.68 | BRPF1 (0.67) | BRPF1BRD1BRD4HDAC8BRPF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170291875-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | UCL BUSINESS PLC (GB) | 2017-10-12 | — | — | US | disclosed |
| EP-3189037-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | UCL Business PLC (GB) | 2017-07-12 | — | — | EP | disclosed |
| WO-2016034512-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | UCL BUSINESS PLC (GB) | 2016-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291875-A1 | QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS | BRD4, BRPF3, BRD3 | BRPF1 104/4885BRD1 4/4885BRD4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.